[Free Webinar] Revolutionizing LNP Development: Smooth Technology Transfer for High-Speed and High-Precision Formulation Exploration and Manufacturing

Quality assessment of proteins, nucleic acids, AAV, LNP, etc. is possible with trace amounts and high throughput.

"Stunner" is a product that allows simultaneous acquisition of UV/Vis concentration, dynamic light scattering (DLS), and static light scattering (SLS) data from a 2μL identical sample. It enables detailed investigation of AAV and adenoviruses to measure total capsid titer and Empty/Full ratios, as well as to obtain payload concentration and size data of lipid nanoparticles all at once. You can analyze concentration, hydrodynamic size, polydispersity, and the presence of aggregates collectively, allowing you to assess the quality of proteins. This way, you can immediately determine whether your AAV, adenoviruses, lipid nanoparticles, or proteins are suitable for your purposes. [Features] ■ Measure up to 96 samples in a batch in 60 minutes*/12 minutes** *When measured by DLS **When measured by UV/Vis only [Applications] ■ AAV/Adenovirus capsid titer ■ AAV/Adenovirus Empty/Full ratio ■ Lipid nanoparticle (LNP) payload amount ■ Aggregate measurement ■ Concentration measurement ■ Sizing & polydispersity ■ B22 & kD *For more details, please refer to the PDF document or feel free to contact us.

• Other protein analysis

Introducing the details of the newly launched LNP production and screening device.

Researchers of lipid nanoparticles (LNPs) spend a tremendous amount of time on screening, optimization, and scaling up experiments to achieve optimal performance, spot-on targeting, and controlled release of active pharmaceutical ingredients (APIs). Factors such as solubility, pH stability, payload release, and encapsulation all depend on particle size, shape, and structure. In other words, to obtain the right formulation, it is necessary to explore a vast number of formulation parameters and process parameters one by one, and even if a perfect formulation is found, scaling up usually means switching equipment and re-optimizing settings. In this webinar, we will introduce a platform, Sunny Suite, that can reduce the time spent on these LNP formulations. ■ Date and Time: February 26 (Monday) 14:00~ ■ Speaker: Yuji Senoo, Field Application Scientist, Unchained Labs, Inc. ■ Register here: https://unchainedlabs.zoom.us/webinar/register/3217065146675/WN_U1o3xQoZRAKHN-A-7b1yqg

• Other protein analysis

Seamlessly transition from formulation condition screening to scale-up and GMP manufacturing. Accelerate LNP product development.

The development of lipid nanoparticles (LNPs) faces many challenges. The formulation, optimization, and scale-up for clinical trials are complex, costly, and a race against time. Our LNP solutions are designed to accelerate all steps of LNP synthesis and characterization. Sunscreen accelerates LNP formulation screening by reducing costs and time, generating up to 96 unique LNP formulations within 6 hours. Next, using Sunshine, you can develop, optimize, and scale up protocols with the appropriate formulations obtained from Sunscreen. When it comes to the clinical trial phase, Sunbather can accommodate LNP production in a GMP environment using the same processes and microfluidic chips (Sunny) utilized by Sunscreen and Sunshine. In this way, the Sun series allows for a seamless transition from screening formulation conditions to scale-up and GMP manufacturing, as they all use the same pumps and microchannel chips. *For product details, please download various materials.

• Other Physics and Chemistry Equipment

Accelerating formulation optimization for vaccine and pharmaceutical development.

The transition from LNP to GMP is a costly and complicated process. Typically, this requires switching equipment, using different flow paths and mixing devices, and essentially re-developing and re-validating everything that has been painstakingly done so far. With Sunbather, the transition to GMP can be done easily thanks to its recording features, interchangeable flow paths, and easily transferable design. Sunbather uses the same mixing process and protocols as the Sunscreen and Sunshine from the same Sun series, allowing for easy transition of adjusted formulation conditions to GMP. - Up to 1.8 L/h - Integrated inline dilution - Fully interchangeable flow paths - A wide variety of mixing devices - Software compliant with 21 CFR Part 11 - Process transferable from Sunshine

• Other Physics and Chemistry Equipment

Efficient mass production of LNPs - Supporting everything from small-scale condition testing to scale-up.

Once we succeed in finding the optimal formulation conditions for sunscreen, let's use Sunshine to adjust the size of the LNP. Furthermore, we will optimize the protocols and processes for scaling up. We will find the ideal flow rate and explore different mixing options. Next, we will adjust these to the appropriate dilution factor that can keep them stable. Once everything is in place, Sunshine will transition to continuous mode, allowing us to produce several dozen liters in a day. In other words, we will achieve process development and scaling up on a single platform. Many researchers have likely been looking forward to the birth of such a groundbreaking system. • 10 experiments in 15 minutes • Fraction & total flow • From 1 mL to continuous flow • Flow rate 0.1 to 30 mL/min • Reusable microfluidic chips • Possible transition of protocols from sunscreen

• Other Physics and Chemistry Equipment

Accelerating formulation optimization for vaccine and pharmaceutical development.

To create the optimal LNP, it takes a tremendous amount of time and effort to examine and pursue formulation conditions. LNPs are nanoparticles composed of multiple lipids. Therefore, it is necessary to find the optimal conditions such as the mixing ratios, the ratio of lipids to payload, and the flow rates during mixing. Furthermore, we must also consider throughput issues. Sunscreen can produce up to 96 types of small LNPs within six hours, thus solving the previous throughput problems. This means that it is possible to explore a greater number of formulation condition investigations in a single day. • Fully automated execution of up to 96 types of condition investigations within six hours • 200 μL to 2 mL per experiment • Flow rate of 0.1 to 30 mL/min • Reusable microfluidic chips • Seamless scale-up through process and protocol optimization

• Other Physics and Chemistry Equipment

We will be exhibiting at the "P-MEC Japan 2025 Pharmaceutical Ingredients and Equipment Exhibition" held at Tokyo Big Sight. During the event, we will showcase various products. We invite all relevant parties to come and visit us. 【Suppliers】 ・LAUDA

Thank you very much for visiting our booth this time. Thanks to you, we had the opportunity to introduce our products and technologies to many customers, making it a very meaningful time. If you have any questions regarding the exhibition content or if you would like to discuss specific considerations or estimates, please feel free to contact us. We will be happy to provide proposals tailored to your needs.

[Lecture Topics] 1. About AI Robotics Tomoya Yokoyama, Section Chief, Robot Policy Office, Industrial Machinery Division, Ministry of Economy, Trade and Industry *The content of the lecture may change. 2. Development of Remote-Controlled Robots Aiming for a Realistic Operating Experience ~Visual and auditory transmission through ultra-low latency, high presence, and high immersion~ Hiroshi Inagaki, Senior Manager, Collaborative Robotics Group, R-Frontier Department, Future Creation Center, Toyota Motor Corporation 3. The Impact of Japanese-Made Humanoids Yasuke Ono, President, Donut Robotics Inc.

[Speaker] Inclusive Design Designer Yoko Nakao [Key Lecture Content] Products are not selling, differentiation is difficult, and regulations are changing. As product development and facility management reach a significant turning point, inclusive design, which involves engaging people who have previously been excluded from the development process to collaboratively think of solutions, is gaining attention as a method for creating new value. Additionally, practicing inclusive design is expected to enhance not only customer engagement but also employee engagement. In this seminar, based on 20 years of experience leading universal design and inclusive design with diverse characteristics both inside and outside a comprehensive electronics manufacturer, I will specifically explain how to practice inclusive design to create new value. [Lecture Items] 1. Inclusive Design as a New Growth Engine 2. Increasing the Resolution of Diversity 3. Inclusive Design Process 4. Side Effects - Ripple Effects on Talent Development and Recruitment 5. Conclusion 6. Q&A / Business Card Exchange

[Lecture Topics] 1. Future Directions of Broadcasting Policy Reiko Kondo, Director-General for Policy Coordination, Ministry of Internal Affairs and Communications 2. The Nature of Broadcasting Systems in the Broadcasting Era Noriaki Saeki, Director of Broadcasting Policy Division, Ministry of Internal Affairs and Communications 3. Latest Trends in Broadcasting Technology Tomoki Nemoto, Director of Broadcasting Technology Division, Ministry of Internal Affairs and Communications 4. Policy Trends Related to Broadcasting Operations and Future Outlook Toshiyuki Sakairi, Director of Broadcasting Operations Division, Ministry of Internal Affairs and Communications 5. Latest Trends in Maintaining and Strengthening Broadcasting Infrastructure and Facility Development Policy Yukari Iimura, Director of Broadcasting Facility Development Promotion Division, Ministry of Internal Affairs and Communications 6. Latest Trends in Broadcasting and Distribution Content Promotion Policy Hiroki Yoshida, Director of Information and Communication Works Promotion Division, Ministry of Internal Affairs and Communications